Trump Says Anthropic No Longer Seen as National Security Threat 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 34th Annual J.P. Morgan Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:30 p.m. PT (7:30 p.m. ET) on Wednesday, January 13, 2016 in San Francisco.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACTS: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
